earn report chang price
thesi updat close best case scenario print
market one could ask agil beat top bottom
line handili offer guidanc expect even
includ solid rare ever happen consid
note preview china macro weak potenti
conservat new cfo perfect
share tomorrow said far
wood true comment tool broadli vs specif
thank agil case outsiz
exposur volatil averag tool market
also key idiosyncrat offset nasd facil ramp
substanti capit deploy
capabl north total cap uniqu
factor option lasergen well manag
recent execut strength keep us o/p rate despit long
memori asset challeng time us
opportun new agil market valu
therein alpha
updat forecast pt forecast creep higher lower
tax rate remain unchang initi impli
msd core low teen ep growth pt move
given conserv view market multipl shift back
summari chang
core ep guid came st expect
broad-bas strength across end market particular
out-performance biopharma
omx bp deliv histor high om
pension account chang hit om
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
tariff expect neg mm hw net incom
 per
food remain flat continu restructur chines
ministri modest growth europ
revenu
china expect hsd
grower pharma lead
way growth
return growth food expect
fx hw impact
modest oper leverag pension adjust
ep
result impact om w/ off-set
income/expens effect net
net interest income/expens expect
inclus keysight bill
tax rate
dilut share count
novemb author approv
capital-expenditure
dividend
repurchas share
off-set dilut minimum
revenu
ep
pharma dd contribut busi
small molecul biopharma perform well
strong perform nasd
newer area strateg focu cell analysi
chemic tough comp
posit on-going market invest area
balanc gain lsag acg driven strength
spectroscopi lc/m suppli servic
demand materi character applic
continu drive robust icp-m growth
environment forens good demand across
global spectroscopi environment lc/m
academ govern fund environ
diagnost clinic driven strong growth
off-set soft-pain manag instrument difficult
compar patholog
food flat expect tough comp slowdown
ministri restructur still in-progress
money move tier tier citi
build channel
expect return growth next year
includ mitig effort includ
bake guidanc next year
china gener sale
strong broad-bas momentum pharma academia
appli environment
anticip return growth food
europ america msd
lsag driven robust growth environment
forens pharma lc/m lc cell analysi icp/m
acg driven strong perform servic
consum well high-teen growth china
dgg driven demand na target enrich
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin novemb
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
